CRENESSITY Trademark

Trademark Overview


On Friday, January 31, 2025, a trademark application was filed for CRENESSITY with the United States Patent and Trademark Office. The USPTO has given the CRENESSITY trademark a serial number of 99975014. The federal status of this trademark filing is APPROVED FOR PUBLICATION as of Monday, November 3, 2025. This trademark is owned by Neurocrine Biosciences, Inc.. The CRENESSITY trademark is filed in the Computer & Software Services & Scientific Services and Medical & Beauty Services & Agricultural Services categories with the following description:

Providing medical research information in the field of pharmaceuticals and clinical trials focusing on congenital adrenal hyperplasia

Providing medical information to patients, medical professionals in the field of congenital adrenal hyperplasia; on-line information services, namely, providing medical information to patients, medical professionals in the field of congenital adrenal hyperplasia
crenessity

General Information


Serial Number99975014
Word MarkCRENESSITY
Filing DateFriday, January 31, 2025
Status680 - APPROVED FOR PUBLICATION
Status DateMonday, November 3, 2025
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing3 - Illustration: Drawing or design which also includes word(s) / letter(s) / number(s)
Published for Opposition DateNOT AVAILABLE

Trademark Statements


Goods and ServicesProviding medical research information in the field of pharmaceuticals and clinical trials focusing on congenital adrenal hyperplasia
Indication of Colors claimedThe color(s) purple, orange, yellow, and dark blue is/are claimed as a feature of the mark.
Description of MarkThe mark consists of four lines with curved top and bottom edges that become progressively larger from left to right and form the overall shape of a conical seashell. The lines appear left to right in a gradient of color from purple to orange to yellow and are positioned above the word CRENESSITY appearing in dark blue.
Goods and ServicesProviding medical information to patients, medical professionals in the field of congenital adrenal hyperplasia; on-line information services, namely, providing medical information to patients, medical professionals in the field of congenital adrenal hyperplasia

Classification Information


International Class042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software.
US Class Codes100, 101
Class Status Code6 - Active
Class Status DateFriday, January 31, 2025
Primary Code042
First Use Anywhere DateSaturday, December 14, 2024
First Use In Commerce DateSaturday, December 14, 2024

International Class044 - Medical services; veterinary services; hygienic and beauty care for human beings or animals; agriculture, horticulture and forestry services.
US Class Codes100, 101
Class Status Code6 - Active
Class Status DateFriday, January 31, 2025
Primary Code044
First Use Anywhere DateSaturday, December 14, 2024
First Use In Commerce DateSaturday, December 14, 2024

Trademark Owner History


Party NameNeurocrine Biosciences, Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressSan Diego, CA 92130

Trademark Events


Event DateEvent Description
Friday, January 31, 2025NEW APPLICATION ENTERED
Friday, January 31, 2025APPLICATION FILING RECEIPT MAILED
Thursday, March 20, 2025TEAS CHANGE OF OWNER ADDRESS RECEIVED
Thursday, March 20, 2025APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Thursday, March 20, 2025TEAS CHANGE OF CORRESPONDENCE RECEIVED
Thursday, May 22, 2025NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Thursday, May 22, 2025NOTICE OF DESIGN SEARCH CODE E-MAILED
Wednesday, June 4, 2025ASSIGNED TO EXAMINER
Monday, June 9, 2025PRIORITY ACTION WRITTEN
Monday, June 9, 2025PRIORITY ACTION E-MAILED
Monday, June 9, 2025NOTIFICATION OF PRIORITY ACTION E-MAILED
Monday, August 18, 2025TEAS RESPONSE TO OFFICE ACTION RECEIVED
Monday, August 18, 2025CORRESPONDENCE RECEIVED IN LAW OFFICE
Monday, August 18, 2025TEAS/EMAIL CORRESPONDENCE ENTERED
Monday, August 18, 2025TEAS REQUEST TO DIVIDE RECEIVED
Monday, August 18, 2025TEAS AMENDMENT OF USE RECEIVED
Wednesday, August 27, 2025ASSIGNED TO LIE
Thursday, August 28, 2025CASE ASSIGNED TO INTENT TO USE PARALEGAL
Monday, August 18, 2025DIVISIONAL REQUEST RECEIVED
Wednesday, October 29, 2025DIVISIONAL PROCESSING COMPLETE
Monday, November 3, 2025APPROVED FOR PUB - PRINCIPAL REGISTER